We suggest potential drugs for these plasma proteins, particularly PLG activators, such as Urokinase, Reteplase, Streptokinase, Alteplase, Anistreplase, Tenecteplase, Desmoteplase, and Defibrotide sodium, as potential therapeutic drugs for treating comorbid MI and AF. Here, PLG is linked to myocardial infarction.